AAM: Generics and biosimilars saved U.S. health system $496 billion in 2025
Generics and biosimilars represented 89% of U.S. prescriptions but only 12% of prescription drug spending in 2025, according to AAM.
Generics
Trump delays generic drug tariffs until 2028
New plan phases in tariffs of 100% in 2028 and 200% in 2029 as manufacturers weigh the cost of shifting production to the U.S.
Dr. Reddy’s launches first-to-market OTC generic of extra-strength Pataday in U.S.
“The first-to-market launch underscores our capabilities in bringing store-brand equivalents of leading OTC brands to the U.S. market.”
Generics at a Crossroad: Webinar replay now available
The webinar offers valuable insights into the business and policy dynamics that shape the future of generic medications.
Webinar preview: “Generics at a Crossroad” to examine the future of generic medicines
Join for an insightful webcast that delves into the vital role of generic medications in our healthcare system.